XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.62

+1.6%

Dec 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (10673)	7/8/1999 5:10:00 PM
From: Arthur Radley	Read Replies (2) of 17367

Good earning's report for Biogen after the bell today. They also mention their psoriasis drug in the release: "''We continue to move our pipeline forward. During the second quarter, Biogen announced that AMEVIVE(TM), a protein that modulates T-cell activity, being studied as a treatment for moderate-to-severe psoriasis, showed a significant therapeutic benefit with an excellent side-effect profile in a Phase II clinical trial. We are very encouraged by these findings and believe that AMEVIVE(TM) offers a novel approach to treating this underserved patient population. We are proceeding aggressively to begin Phase III registrational studies in North America and Europe after making further improvements in the commercial process. We have also begun human trials with ANTOVA(TM), a novel immunomodulator, in islet cell transplantation for diabetes, in renal transplantation, and in lupus.''

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next